General References


Iaccarino G, Izzo R, Trimarco V et al. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Clin Pharmacol Ther 2006; 80:633-45.

Ianculescu AG, Friesema EC, Visser TJ, Giacomini KM, Scanlan TS. Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. Mol Biosyst 2010; 6:1403-10.

Iankova I, Chavey C, Clapé C et al. Regulator of G protein signaling-4 controls fatty acid and glucose homeostasis. Endocrinology 2008; 149:5706-12.

Iannaccone CK, Lee YC, Cui J et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology 2011; 50:40-6.

Iatsimirskaia E, Tulebaev S, Storozhuk E et al. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997; 61:554-62.

Iatsimirskaia EA, Gregory ML, Anderes KL et al. Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. Pharm Res 2002; 19:202-8.

Iba MM, Shin M, Caccavale RJ. Cytochromes P4501 (CYP1): catalytic activities and inducibility by diesel exhaust particle extract and benzo[a]pyrene in intact human lung ex vivo. Toxicology 2010; 273:35-44.

Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in familiar early onset of Alzheimer’s disease: a case report. Pharmacopsychiatry 2005; 38:178-9.

Ibáñez P, Lesage S, Janin S et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 2009; 66:102-8.

Ibeanu GC, Blaisdell J, Ferguson RJ et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999; 290:635-40.

Ibeanu GC, Blaisdell J, Ghanayem BI et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8:129-35.

Ibeanu GC, Goldstein JA, Meyer U et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286:1490-5.

Ibrahim A, Karim A, Feldman J, Kharasch E. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg 2002; 95:667-73.

Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003; 98:853-61.

Ibrahim NK, Yariz KO, Bondarenko I et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011. doi:10. 1158/1078-0432. CCR-11-1151.

Ibrahim ZS, Ishizuka M, Soliman M et al. Protection by Nigella sativa against carbon tetrachloride-induced downregulation of hepatic cytochrome P450 isozymes in rats. Jpn J Vet Res 2008; 56:119-28.

Ichihara S, Yamada Y, Kato K et al. Association of a polymorphism of ABCB1 with obesity in Japanese individuals. Genomics 2008; 91:512-6.

Ichinose H, Ohye T, Fujita K et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson’s disease and schizophrenia. J Neural Transm Park Dis Dement Sect 1994; 8:149-58.

Ichinose H, Ohye T, Takahashi E et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8:236-42.

Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T. Molecular genetics of dopa-responsive dystonia. Biol Chem 1999; 380:1355-64.

Idbaih A, Carvalho Silva R, Crinière E et al. Genomic changes in progression of low-grade gliomas. J Neurooncol 2008; 90:133-40.

Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 2007; 19:606-11.

Ide H, Seligson DB, Memarzadeh S et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci USA 2002; 99:14404-9.

Ide S, Kobayashi H, Ujike H et al. Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J 2006; 6:179-88.

Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I. Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms. J Clin Pharmacol 2009; 49:1309-17.

Idelman G, Taylor JG, Tongbai R et al. Functional profiling of uncommon VCAM1 promoter polymorphisms prevalent in African American populations. Hum Mutat 2007; 28:824-9.

Identification of five partial ABC genes in the liver of the Antarctic fish Trematomus bernacchii and sensitivity of ABCB1 and ABCC2 to Cd exposure. Environ Pollut 2010; 158:2746-56.

Idiaquez J, Alvarez G, Villagra R, San Martin RA. Cholinergic supersensitibity of the iris in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1994; 57:1544-5.

Idkowiak J, Malunowicz EM, Dhir V et al. Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche. J Clin Endocrinol Metab 2010; 95:3418-27.

Idkowiak J, O’Riordan S, Reisch N et al. Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 2011; 96:453-62.

Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009; 5:703-29.

Ieiri I, Nishimura C, Maeda K et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 2011; 21:495-505.

Ieiri I, Suwannakul S, Maeda K et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2007; 82:541-7.

Ieiri I, Yamada S, Seto K et al. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 2003; 36:192-6.

Igarashi K, Kasuya F, Fukui M, Usuki E, Castagnoli N Jr. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Life Sci 1995; 57:2439-46.

Igarashi T, Sakuma T, Isogai M, Nagata R, Kamataki T. Marmoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs. Arch Biochem Biophys 1997; 339:85-91.

Igata-Yi R, Igata T, Ishizuka K. Apolipoprotein E genotype and psychosis. Biol Psychiatry 1997; 41:906-8.

Iglarz M, Benessiano J, Philip I et al. Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 2002; 39:209-13.

Ihara K, Inuo M, Kuromaru R et al. The Leu544Ile polymorphism of the growth hormone receptor gene affects the serum cholesterol levels during GH treatment in children with GH deficiency. Clin Endocrinol 2007; 67:212-7.

Iida A, Saito S, Sekine A et al. Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGTB15, and UGT8. J Hum Genet 2002; 47:505-10.

Iida I, Miyata A, Arai M et al. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5’-hydroxylation. Drug Metab Dispos 2004; 32:7-9.

Iidaka T, Ozaki N, Matsumoto A et al. A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 2005; 25:6460-6.

Iijima H, Emi M, Wada M et al. Association of an intronic haplotype of the LIPC gene with hyperalphalipoproteinemia in two independent populations. J Hum Genet 2008; 53:193-200.

Iijima M, Momose I, Ikeda D. Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem 2010; 74:1913-9.

Iijima M, Tariba T, Poorkaj P et al. A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport 1999; 10:497-501.

Iizuka K, Kusunoki A, Machida T, Hirafuji M. Angiotensin II reduces membranous angiotensin-converting enzyme 2 in pressurized human aortic endothelial cells. J Renin Angiotensin Aldosterone Syst 2009; 10:210-5.

Ikebuchi Y, Ito K, Takada T, Anzai N, Kanai Y, Suzuki H. Receptor for activated C-kinase 1 regulates the cell surface expression and function of ATP binding cassette G2. Drug Metab Dispos 2010; 38:2320-8.

Ikeda H, Taira N, Hara F et al. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 2010; 12:43.

Ikeda K, Utoguchi N, Tsutsui H et al. In vitro approaches to evaluate placental drug transport by using differentiating JEG-3 human choriocarcinoma cells. Basic Clin Pharmacol Toxicol 2011; 108:138-45.

Ikeda M, Iwata N, Suzuki T et al. Association analysis of chromosome 5 GABAA receptor cluster in Japanese schizophrenia patients. Biol Psychiatry 2005; 58:440-5.

Ikeda M, Yamanouchi Y, Kinoshita Y et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008; 9:1437-43.

Ikeda R, Vermeulen LC, Lau E et al. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. Int J Oncol 2011; 38:513-9.

Ikeda S, Kurose K, Jinno H et al. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab 2005; 86:314-9.

Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet 2011; 26:60-70.

Ikediobi O, Aouizerat B, Xiao Y, Gandhi M, Gebhardt S, Warnich L. Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 2011; 5:265-82.

Ikehata A, Hiwatashi N, Kinouchi Y, Ito K, Yamazaki H, Toyota T. Leukotriene B4 omega-hydroxylase activity in polymorphonuclear leukocytes from patients with inflammatory bowel disease. Prostaglandins Leukot Essent Fatty Acids 1993; 49:489-94.

Ikejiri M, Wada H, Sakamoto Y et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol 2010; 92:302-5.

Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Molec Endocr 1989; 3:1399-408.

Ikezoe T, Hisatake Y, Takeuchi T et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64:7426-31.

Ilani T, Ben-Shachar D, Strous RD et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Nat Acad Sci USA 2001; 98:625-8.

Illarioshkin SN, Igarashi S, Ondera O et al. Trinucleotide repeat length and rate of progresión of Huntington’s disease. Ann Neurol 1994; 36:630-5.

Illi A, Kampman O, Anttila S et al. Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol 2003; 13:147-51.

Illi A, Setälä-Soikkeli E, Viikki M et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009; 20:1125-8.

Illig T, Bongardt F, Schöpfer A et al. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J Clin Endocrinol Metab 2004; 9:5053-8.

Illingworth NA, Boddy AV, Daly AK, Veal GJ. Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol 2011; 162:989-99.

Illmer T, Schuler US, Thiede C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-62.

Im YB, Ha I, Kang KW, Lee MY, Han HK. Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells. Nutr Cancer 2009; 61:538-43.

Imaeda Y, Kawamoto T, Tobisu M et al. Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors. Bioorg Med Chem 2008; 16:3125-40.

Imaeda Y, Miyawaki T, Sakamoto H et al. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. Bioorg Med Chem 2008; 16:2243-60.

Imai J, Ieiri I, Mamiya K et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10:85-9.

Imai T, Taketani M, Suzu T, Kusube K, Otagiri M. In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos 1999; 27:942-6.

Imaizumi T, Higaki Y, Hara M et al. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis 2009; 30:1729-34.

Imaoka S, Hashizume T, Funae Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet 2005; 20:478-84.

Imaoka S, Hayashi K, Hiroi T, Yabusaki Y, Kamataki T, Funae Y. A transgenic mouse expressing human CYP4B1 in the liver. Biochem Biophys Res Commun 2001; 284:757-62.

Imaoka S, Yamada T, Hiroi T et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 1996; 51:1041-50.

Imaoka S, Yoneda Y, Sugimoto T et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett 2001; 166:119-23.

Imaoka S, Yoneda Y, Sugimoto T et al. CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem Biophys Res Commun 2000; 277:776-80.

Imberti D, Pierfranceschi MG. Successful protein C concentrate administration during initiation of oral anticoagulation in adult patients with severe congenital protein C deficiency: report of two cases. Pathophysiol Haemost Thromb 2008; 36:53-7.

Imbimbo BP, Giardina GA. γ-secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes. Curr Top Med Chem 2011; 11:1555-70.

Imbimbo BP, Giardino L, Sivilia S et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis 2010; 20:159-73.

Imbimbo BP, Panza F, Frisardi V et al. Therapeutic intervention for Alzheimer’s disease with γ-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011; 20:325-41.

Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer’s disease. Curr Opin Investig Drugs 2009; 10:721-30.

Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front Aging Neurosci 2010; 2:19.

Imperato-McGinley J, Gautier T, Peterson RE, Shackleton C. The prevalence of 5 alpha-reductase deficiency in children with ambiguous genitalia in the Dominican Republic. J Urol 1986; 136:867-73.

Imperato-McGinley J, Peterson RE, Stoller R, Goodwin WE. Male pseudohermaphroditism secondary to 17 beta-hydroxysteroid dehydrogenase deficiency: gender role change with puberty. J Clin Endocrinol Metab 1979; 49:391-5.

Impraim C, Wang G, Yoshida A. Structural mutation in a major human aldehyde dehydrogenase gene results in loss of enzyme activity. Am J Hum Genet 1982; 34:837-41.

In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130-7.

Inaba M, Sato H, Abe Y, Umemura S, Ito K, Sakai H. Expression and significance of c-met protein in papillary thyroid carcinoma. Tokai J Exp Clin Med 2002; 27:43-9.

Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Lett 1997; 93:215-9.

Inaba T, Nebert DW, Burchell B et al. Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995; 73:331-8.

Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003; 13:163-8.

Inagaki Y, Mashima Y, Fuse N et al. Polymorphism of beta-adrenergic receptors and susceptibility to open-angle glaucoma. Mol Vis 2006; 12:673-80.

Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer’s disease. FEBS J 2008; 275:625-32.

Inestrosa NC, Sagal JP, Colombres M. Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell Biochem 2005; 38:299-317.

Infante J, Llorca J, Rodero L, Palacio E, Berciano J, Combarros O. Polymorphism at codon 174 of the prion-like protein gene is not associated with sporadic Alzheimer’s disease. Neurosci Lett 2002; 332:213-5.

Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005; 207(2 Suppl):52-6.

Ingelman-Sundberg M, Johansson I, Yin H et al. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993; 10:447-52.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526.

Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. Hum Genomics 2010; 4:402-5.

Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.

Ingle JN. Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res 2008; 10:17.

Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008; 112(3 Suppl):695-9.

Ingle JN, Buzdar AU, Schaid DJ et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010; 70:3278-86.

Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010; 28:4674-82.

Ingles SA, Ross RK, Yu MC et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89:166-70.

Inglis GC, Kenyon CJ, Szpirer C, Klinga-Levan K, Sutcliffe RG, Connell JM. Microsatellite polymorphism analysis allows the individual assignment of the rat 11 beta-hydroxylase gene (Cyp11b1) and the rat aldosterone synthase gene (Cyp11b2) to chromosome 7 using rat x mouse somatic cell hybrids and identifies differences between and within various rat strains. J Mol Endocrinol 1995; 14:303-11.

Ingram EM, Spillantini MG. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med 2002; 8:555-62.

Inno A, Basso M, Vecchio FM et al. Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol 2011; 11:32.

Innocenti F, Grimsley C, Das S et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12:725-33.

Innocenti F, Kroetz DL, Schuetz E et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604-14.

Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-8.

Inomata S, Nagashima A, Itagaki F et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78:647-55.

Inomoto T, Shirakami A, Kawauchi S et al. Prothrombin Tokushima: characterization of dysfunctional thrombin derived from a variant of human prothrombin. Blood 1987; 69:565-9.

Inoue E, Takahashi Y, Imai Y, Kamataki T. Development of bacterial expression system with high yield of CYP3A7, a human fetus-specific form of cytochrome P450. Biochem Biophys Res Commun 2000; 269:623-7.

Inoue H, Yamasue H, Tochigi M et al. Effect of tryptophan hydroxylase-2 gene variants on amygdalar and hippocampal volumes. Brain Res 2010; 1331:51-7.

Inoue I, Nakajima T, Williams CS et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99:1786-97.

Inoue K, Inazawa J, Nakagawa H et al. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22. 1 by fluorescence in situ hybridization. Jpn J Hum Genet 1992; 37:133-8.

Inoue K, Miura M, Satoh S et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007; 29:299-304.

Inoue K, Negishi M. Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J Biol Chem 2008; 283:10425-32.

Inoue K, Yamazaki H, Shimada T. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. Xenobiotica 1998; 28:403-11.

Inoue N, Watanabe M, Morita M et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol 2011; 163:318-23.

Inoue S, Hashiguchi M, Chiyoda T, Sunami Y, Tanaka T, Mochizuki M. Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics 2007; 8:41-7.

Inoue T, Kira R, Nakao F et al. Contribution of the interleukin 4 gene to susceptibility to subacute sclerosing panencephalitis. Arch Neurol 2002; 59:822-7.

Inoue T, Miki Y, Abe K et al. The role of estrogen-metabolizing enzymes and estrogen receptors in human epidermis. Mol Cell Endocrinol 2011; 344:35-40.

Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 2008; 36:2429-33.

Inouye K, Shinkyo R, Takita T, Ohta M, Sakaki T. Metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) by human cytochrome P450-dependent monooxygenase systems. J Agric Food Chem 2002; 50:5496-502.

Inowa T, Hishikawa K, Matsuzaki Y et al. GADD45β determines chemoresistance and invasive growth of side population cells of human embryonic carcinoma. Stem Cells Int 2010. doi:10. 4061/2010/782967.

International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-64.

Inui H, Maeda A, Ohkawa H. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5. Biochemistry 2007; 46:10213-21.

Inuzuka Y, Okuda J, Kawashima T et al. Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation 2009; 120:1695-703.

Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32:451-78.

Ionov M, Burchell V, Klajnert B, Bryszewska M, Abramov AY. Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity. Neuroscience 2011; 180:229-37.

Iordanidou M, Tavridou A, Petridis I et al. The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. Clin Chim Acta 2010; 411:167-71.

Iordanidou M, Tavridou A, Vasiliadis MV et al. The -759C/T polymorphism of the 5-HT2C receptor is associated with type 2 diabetes in male and female Caucasians. Pharmacogenet Genomics 2008; 18:153-9.

Ipatova OM, Prozorovskaia NN, Baranova VS, Guseva DA. Biological activity of linseed oil as the source of omega-3 alpha-linolenic acid. Biomed Khim 2004; 50:25-43.

Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnürch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release 2010; 147:62-9.

Iqbal J, Sakloetsakun D, Bernkop-Schnürch A. Thiomers: Inhibition of cytochrome P450 activity. Eur J Pharm Biopharm 2011; 78:361-5.

Iqbal Kring SI, Barefoot J, Brummett BH et al. Associations between APOE variants and metabolic traits and the impact of psychological stress. PLoS One 2011. doi:10. 1371/journal. pone. 0015745.

Iqbal M, Gibb W, Matthews SG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology 2011; 152:1067-79.

Iram SH, Cole SP. Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. J Biol Chem 2011; 286:7202-13.

Irie H, Asano-Hoshino A, Sekino Y, Nogami M, Kitagawa T, Kanda H. Striking LD50 variation associated with fluctuations of CYP2E1-positive cells in hepatic lobule during chronic CCl4 exposure in mice. Virchows Arch 2010; 456:423-31.

Irizarry MC, Deng A, Lleo A et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 2004; 90:1132-43.

Ironside JW, Sutherland K, Bell JE et al. A new variant of Creutzfeldt-Jakob disease: neuropathological and clinical features. Cold Spring Harbor Symp Quant Biol 1996; 61:523-30.

Irshaid Y, Branch RA, Adedoyin A. Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos 1996; 24:164-71.

Irusta G, Murphy MJ, Perez WD, Hennebold JD. Dynamic expression of epoxyeicosatrienoic acid synthesizing and metabolizing enzymes in the primate corpus luteum. Mol Hum Reprod 2007; 13:541-8.

Irvin WJ Jr, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 2011; 29:3232-9.

Isaac MT. Treating depression with SNRIs: who will benefit most? CNS Spectr 2008; 13(7 Suppl 11):15-21.

Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM. The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 2004; 89:3858-63.

Isaacs C, Herbolsheimer P, Liu MC et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011; 125:137-43.

Isayama F, Froh M, Bradford BU et al. The CYP inhibitor 1-aminobenzotriazole does not prevent oxidative stress associated with alcohol-induced liver injury in rats and mice. Free Radic Biol Med 2003; 35:1568-81.

Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 2000; 22:695-705.

Isbister GK, Friberg LE, Hackett LP, Duffull SB. Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal. Clin Pharmacol Ther 2007; 81:821-7.

Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O, Raunio H. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 2001; 70:47-54.

Isermann B, Vinnikov IA, Madhusudhan T et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13:1349-58.

Ishak KJ, Tan Y, Glass J, Luong D, Caro JJ. Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. Clin Ther 2008; 30:1251-63.

Ishida K, Honda M, Shimizu T, Taguchi M, Hashimoto Y. Stereoselective metabolism of carvedilol by the beta-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells. Biol Pharm Bull 2007; 30:1930-3.

Ishida K, Taguchi M, Akao T, Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells. Biol Pharm Bull 2009; 32:513-6.

Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, Hashimoto Y. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 2008; 31:1297-300.

Ishigaki Y, Oikawa S, Suzuki T et al. Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 2000; 275:31269-73.

Ishigam M, Uchiyama M, Kondo T et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 2001; 18:622-31.

Ishigami M, Honda T, Takasaki W et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 2001; 29:282-8.

Ishigami M, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes. Drug Metab Dispos 2002; 30:904-10.

Ishiguro A, Kubota T, Sasaki H, Iga T. A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype. Clin Chim Acta 2004; 347:217-21.

Ishiguro A, Kubota T, Soya Y et al. High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal Biochem 2005; 337:256-61.

Ishiguro N, Senda C, Kishimoto W, Sakai K, Funae Y, Igarashi T. Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica 2000; 30:71-80.

Ishihara T, Hong M, Zhang B et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24:751-62.

Ishii K, Tanaka S, Kagami K et al. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. Cancer Invest 2010; 28:220-9.

Ishii T, Wakabayashi R, Kurosaki H, Gemma A, Kida K. Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. J Hum Genet 2011; 56:41-6.

Ishii Y, Nakamura K, Tsutsumi K, Kotegawa T, Nakano S, Nakatsuka K. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol 2000; 40:193-9.

Ishii Y, Takeda S, Yamada H. Modulation of UDP-glucuronosyltransferase activity by protein-protein association. Drug Metab Rev 2010; 42:140-53.

Ishikawa C, Ozaki H, Nakajima T et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004; 49:582-5.

Ishikawa M, Yoshii H, Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotechnol Biochem 2005; 69:246-8.

Ishikawa T, Nakagawa H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol 2009; 8:5-24.

Ishikawa T, Nakagawa H, Hagiya Y, Nonoguchi N, Miyatake S, Kuroiwa T. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Adv Pharmacol Sci 2010. doi:10. 1155/2010/587306.

Ishikawa Y, Nagai J, Okada Y, Sato K, Yumoto R, Takano M. Function and expression of ATP-binding cassette transporters in cultured human Y79 retinoblastoma cells. Biol Pharm Bull 2010; 33:504-11.

Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl 3:27-36.

Ishizawa M, Komatsu H. Pharmacological study and clinical effect of HIV protease inhibitor amprenavir. Nippon Yakurigaku Zasshi 2001; 117:59-64.

Ishizawar DC, Janosko KM, Teuteberg JJ, Cadaret LM, Mathier MA, McNamara DM. The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers. Clin Transl Sci 2008; 1:151-4.

Isidor B, Dagoneau N, Huber C et al. A gene responsible for Ghosal hemato-diaphyseal dysplasia maps to chromosome 7q33-34. Hum Genet 2007; 121:269-73.

Isin EM, Guengerich FP. Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 2006; 281:9127-36.

Isin EM, Guengerich FP. Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4. J Biol Chem 2007; 282:6863-74.

Ising M, Depping AM, Siebertz A et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 2008; 28:389-98.

Iskander K, Jaiswal AK. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact 2005; 153-4:147-57.

Isla Tejera B, Aumente Rubio MD, Martínez-Moreno J, Reyes Malia M, Arizón JM, Suárez García A. Pharmacogenetic analysis of the absorption kinetics of cyclosporine in a population of Spanish cardiac transplant patients. Farm Hosp 2009; 33:324-9.

Islam R, Anzai N, Ahmed N et al. Mouse organic anion transporter 2 (mOat2) mediates the transport of short chain fatty acid propionate. J Pharmacol Sci 2008; 106:525-8.

Islam SI, Masuda QN, Bolaji OO, Shaheen FM, Sheikh IA. Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients. Ther Drug Monit 1996; 18:624-6.

Islam T, McConnell R, Gauderman WJ, Avol E, Peters JM, Gilliland FD. Ozone, oxidant defense genes, and risk of asthma during adolescence. Am J Respir Crit Care Med 2008; 177:388-95.

Ismail D, Smith VV, de Lonlay P et al. Familial focal congenital hyperinsulinism. J Clin Endocrinol Metab 2011; 96:24-8.

Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31:99-109.

Ismail R, Teh LK, Amir J, Alwi Z, Lopez CG. Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia. J Clin Pharm Ther 2003; 28:279-84.

Ismail S, Hanapi NA, Ab Halim MR, Uchaipichat V, Mackenzie PI. Effects of Andrographis paniculata and Orthosiphon stamineus extracts on the glucuronidation of 4-methylumbelliferone in human UGT isoforms. Molecules 2010; 15:3578-92.

Isobe T, Hichiya H, Hanioka N et al. Different effects of desipramine on bufuralol 1’’-hydroxylation by rat and human CYP2D enzymes. Biol Pharm Bull 2005; 28:634-40.

Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol Toxicol 1999; 84:143-6.

Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. Basic Clin Pharmacol Toxicol 2006; 99:168-72.

Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Basic Clin Pharmacol Toxicol 2004; 95:120-3.

Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998; 54:561-5.

Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32:1121-31.

Isomura T, Haraguchi S, Miyamoto K, Tsutsui K, Nakamura Y, Nakamura M. Estrogen biosynthesis in the gonad of the frog Rana rugosa. Gen Comp Endocrinol 2011; 170:207-12.

Isomura Y, Yamaji Y, Ohta M et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol 2010; 45:1045-52.

Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet 2000; 67:986-90.

Isozaki K, Hirota S. Gain-of-function mutations of receptor tyrosine kinases in gastrointestinal stromal tumors. Curr Genomics 2006; 7:469-75.

Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-12.

Israel E, Drazen JM, Liggett SB et al. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124:183-6.

Israel E, Drazen JM, Liggett SB et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.

Israni AK, Li N, Sidhwani S et al. Association of hypertension genotypes and decline in renal function after kidney transplantation. Transplantation 2007; 84:1240-7.

Issaeva N, Thomas HD, Djureinovic T et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 2010; 70:6268-76.

Istrate MA, Nussler AK, Eichelbaum M, Burk O. Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun 2010; 393:688-93.

Itäaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, Finel M. Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 2009; 37:768-75.

Itabashi S, Arai H, Higuchi S, Sasaki H, Trojanowski JQ. APOE e4 allele in Alzheimer’s and non-Alzheimer’s dementias. Lancet 1996; 348:960-1.

Itagaki S, Gopal E, Zhuang L et al. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). Pharm Res 2006; 23:1209-16.

Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter. Drug Metab Pharmacokinet 2003; 18:238-44.

Ito A, Miyake M, Morishita M, Ito K, Torii S, Sakamoto T. Dexamethasone reduces lung eosinophilia, and VCAM-1 and ICAM-1 expression induced by Sephadex beads in rats. Eur J Pharmacol 2003; 468:59-66.

Ito H, Matsuo K, Hosono S et al. Association between CYP7A1 and the risk of proximal colon cancer in Japanese. Int J Mol Epidemiol Genet 2010; 1:35-46.

Ito I, Kawaguchi Y, Kawasaki A et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010; 62:890-5.

Ito I, Kawasaki A, Ito S et al. Replication of association between FAM167A(C8orf13)-BLK region and rheumatoid arthritis in a Japanese population. Ann Rheum Dis 2010; 69:936-7.

Ito I, Kawasaki A, Ito S et al. Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population. Arthritis Rheum 2009; 60:553-8.

Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004; 57:473-86.

Ito K, Kubota Y, Toda T, Suto S, Ikarashi N, Sugiyama K. Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein. Drug Metab Pharmacokinet 2009; 24:108-13.

Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm Res 1999; 16:225-31.

Ito K, Satoh T, Watanabe Y et al. Effects of Kampo medicines on CYP and P-gp activity in vitro. Biol Pharm Bull 2008; 31:893-6.

Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, Sugiyama Y. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 1997; 272:16-22.

Ito K, Uchida Y, Ohtsuki S et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 2011; 100:3939-50.

Itoda M, Saito Y, Maekawa K et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet 2004; 19:308-12.

Itoda M, Saito Y, Shirao K et al. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet 2003; 18:212-7.

Itoga S, Nomura F, Harada S, Tsutsumi M, Takase S, Nakai T. Mutations in the exons and exon-intron junction regions of human cytochrome P-4502E1 gene and alcoholism. Alcohol Clin Exp Res 1999; 23(4 Suppl):13-6.

Itoh T, Koshiba S, Kigawa T, Kikuchi A, Yokoyama S, Takenawa T. Role of the ENTH domain in phosphatidylinositol-4,5-biosphate binding and endocytosis. Science 2001; 291:1047-51.

Itoh T, Takemura H, Shimoi K, Yamamoto K. A 3D model of CYP1B1 explains the dominant 4-hydroxylation of estradiol. J Chem Inf Model 2010; 50:1173-8.

Iturralde-Torres P, Medeiros-Domingo A. Genetic in long QT syndromes. Arch Cardiol Mex 2009; 79 Suppl 2:26-30.

Itzhaki RF, Dobson CB, Shipley SJ, Wozniak MA. The role of viruses and of APOE in dementia. Ann N Y Acad Sci 2004; 1019:15-8.

Itzhaki RF, Lin WR, Shang D et al. Herpes simplex virus type 1 in brain and risk for Alzheimer’s disease. Lancet 1997; 349:241-4.

Iudicibus SD, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 2011; 17:1095-108.

Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration. J Pharmacol Exp Ther 2011; 337:710-7.

Ivanov V, Cha J, Ivanova S, Kalinovsky T, Rath M, Niedzwiecki A. Nutrient supplementation modulates angiotensin II-mediated atherosclerosis in ApoE KO mice. Mol Med Report 2010; 3:417-25.

Iwahashi K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry 1994; 36:781-2.

Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 1995; 18:233-6.

Iwahashi K, Suwaki H, Matsuo Y, Ichikawa Y, Hosokawa K. Correspondence of increased debrisoquine 4-monooxygenase activity with seizure-susceptibility in Mongolian gerbils. J Neurol Sci 1994; 121:18-21.

Iwahashi K, Yoshihara E, Nakamura K et al. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. Neuropsychobiology 1999; 39:33-7.

Iwahori T, Matsuura T, Maehashi H et al. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 2003; 37:665-73.

Iwai C, Akita H, Kanazawa K et al. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003; 146:106-9.

Iwai C, Akita H, Shiga N et al. Suppressive effect of the Gly389 allele of the 1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 2002; 66:723-8.

Iwai M, Kanno H, Senba I, Nakaoka H, Moritani T, Horiuchi M. Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem Biophys Res Commun 2011; 406:123-6.

Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 2004; 49:123-8.

Iwai N, Katsuya T, Ishikawa K et al. Human prostacyclin synthase gene and hypertension: the Suita Study. Circulation 1999; 100:2231-6.

Iwaki K, Sakaeda T, Kakumoto M et al. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. J Pharm Pharmacol 2006; 58:1617-22.

Iwamoto K, Ikeda J, Nito M et al. Effect of oxatomide, an antiallergic agent, on QT interval in dogs. Arzneimittelforschung 2001; 51:971-6.

Iwamoto K, Ikeda J, Nito M et al. Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval in dogs. Nippon Yakurigaku Zasshi 2001; 117:401-9.

Iwamoto M, Kassahun K, Troyer MD et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008; 48:209-14.

Iwamoto N, Lu R, Tanaka N, Abe-Dohmae S, Yokoyama S. Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler Thromb Vasc Biol 2010; 30:1446-52.

Iwamoto N, Yokoyama S. Protein kinase D regulates the adiponectin gene expression through phosphorylation of AP-2: A common pathway to the ABCA1 gene regulation. Atherosclerosis 2011; 216:90-6.

Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N, Okuda M. Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. Pharmacotherapy 2010; 30:661-5.

Iwamoto T, Monma F, Fujieda A, Nakatani K, Katayama N, Okuda M. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther 2011; 33:1077-80.

Iwanaga K, Hayashi M, Hamahata Y et al. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. Drug Metab Dispos 2010; 38:1286-94.

Iwano S, Asanuma F, Nukaya M, Saito T, Kamataki T. CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 2005; 337:708-12.

Iwano S, Nukaya M, Saito T, Asanuma F, Kamataki T. A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 2005; 335:220-6.

Iwasaki H, Okabe T, Takara K, Yoshida Y, Hanashiro K, Oku H. Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of nitidine. Cancer Chemother Pharmacol 2010; 66:953-9.

Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22:328-35.

Iwasaki K, Uno Y. Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica 2009; 39:578-81.

Iwasaki M, Hamada GS, Nishimoto IN et al. Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Nutr Cancer 2010; 62:466-75.

Iwase M, Kurata N, Ehana R, Nishimura Y, Masamoto T, Yasuhara H. Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro. Hum Exp Toxicol 2006; 25:715-21.

Iwata H, Fujita K, Kushida H et al. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 1998; 55:1315-25.

Iwata H, Sato H, Suzuki R et al. A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol 2011; 38:1653-61.

Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004; 32:1351-8.

Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet 2005; 20:34-45.

Iwata N, Cowley DS, Radel M, Roy-Byrne PP, Goldman D. Relationship between a GABAA alpha 6 Pro385Ser substitution and benzodiazepine sensitivity. Am J Psychiatry 1999; 156:1447-9.

Iwatsubo T, Hirota N, Ooie T et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73:147-71.

Iwatsubo T, Suzuki H, Shimada N et al. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 1997; 282:909-19.

Iyengar RR, Lynch JK, Mulhern MM et al. An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists. Bioorg Med Chem Lett 2007; 17:874-8.

Iyer KR, Sinz MW. Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations. Chem Biol Interact 1999; 118:151-69.

Izawa A, Schatton T, Frank NY et al. A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun 2010; 394:646-52.

Izawa M, Taniguchi F, Uegaki T et al. Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues. Fertil Steril 2011; 95:33-9.

Izuishi K, Wakabayashi H, Ohnishi T, Maeta H, Maeba T, Ichikawa Y. Effects of an immunosuppressive agent, tacrolimus (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems in rat liver microsomes. Int J Biochem Cell Biol 1997; 29:921-8.

Izumi T, Io K, Matsui M et al. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc Natl Acad Sci USA 2010; 107:20798-803.

Izumiya Y, Kojima S, Kojima S et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011; 214:415-21.

Izzedine H, Hulot JS, Villard E et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194:1481-91.

Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69:1777-98.